Food Allergy

The approval is based upon phase 3 findings from the OUtMATCH study, representing the first treatment for adult and pediatric patients with accidental exposure to 1 or more food allergens.

These data also showed that basophil activation test can be a particularly precise biomarker of allergy compared to tolerance among children who are egg-allergic children.

The seismic shifts in mentality for allergy management and the strides made in immunotherapy have kept parents of children with allergies hopeful, but changes are still needed.

The decision by the FDA is a step closer to omalizumab’s potential approval, making it the potential first medicine to reduce reactions to many different food allergens after accidental exposure.

This new recommendation by the European Academy of Allergy and Clinical Immunology was put forward to help guide clinical practices.

Data show how care providers shifted their mindsets to prioritize efficacy, safety, tolerability and availability factors during the 2022 formula supply shortage and recall crises.

This new analysis was described as the first estimate on the prevalence in Europe of specific TNA and sensitization.

The agency’s guideline updates were announced, with the overall goal being to help food facilities in their adherence to current good manufacturing practices.

This research shows that a basophil activation test can support decision-making by clinicians when re-introduction of baked eggs in patients with allergies is a treatment being considered.

This analysis on a larger study population led to results which add useful data to the growing literature on sesame thresholds and may even help to assess sesame safe doses used in risk management.

The new research in this study indicates that both types of food challenges may be equally useful when conducted by trained staff who use strict objective stop criteria.

This expanded upon the limited data available on risks of precautionary allergen label food introduction for those with allergies, the results of which suggest new possibilities for future allergy management.

This new research is the first to examine the use of the iMAP milk ladder in primary care settings for younger patients with IgE-mediated cow’s milk protein allergy.

These new findings may lead to a more accessible and rigorous approach to diagnosis, with a possibility of reduction of over-diagnosis.

New data indicated the development of allergy was not affected by mothers’ consumption of eggs in the very early neonatal period, expanding the body of research exploring food sensitization.

New data on oral immunotherapy to food allergens shows promise for the treatment, though more information with standard interventions and regimens is needed to gain certainty on the efficacy and safety.

Future studies of socioeconomic factors and environmental elements contributing may help to further explain the causes of food allergies and inform targeted interventions and management.

This new data indicates that the peanut patch was efficacious and safe in children with peanut allergies in this age bracket, expanding the body of research on desensitization for toddlers and young children.

Data presented at the American Society for Clinical Pharmacology and Therapeutics annual meeting show promise for Utuly, a novel intranasal epinephrine spray for treating anaphylaxis.

New data on peanut allergy and Pediatric Quality of Life Inventory scores sheds light on the burden of allergy on adolescents.

“These findings are exciting for us, and our overarching goal is to develop microbial biotherapeutics to treat food allergies," Mustafa Özçam says in an interview with HCPLive.

In a recent letter to the editor, a newly-developed tool to assess one’s satisfaction with life when dealing with food allergy was introduced.

A recent study reviewed several educational interventions designed to promote food allergy literacy and knowledge for both parents and children.

Data from AAAAI 2023 suggests that gut microbial composition, function, and metabolic activity are implicated in the efficacy of peanut oral immunotherapy in children with peanut allergy.

Recent data, presented at the AAAAI annual meeting, showed that oral sesame desensitization through crushed seeds and tahini was efficacious and safe for pediatric patients.

Individuals with comorbid asthma, allergic rhinitis, and oral allergy syndrome had higher rates of eosinophilic esophagitis.

An interview featured Bird discussing data from his AAAAI annual meeting presentation on a new oral immunotherapy product for those with peanut allergies.

Late-breaking data presented by Dr. Christopher Warren indicates travelers with food allergy lack confidence in regulations and accommodations put in place for air travel.

"You want to be empowering children to be proactive and managing their medical condition in the healthiest, safest possible way," Dr. Christopher Warren said in an interview at AAAAI 2023.

Dr. Christopher Warren discusses the study he presented at AAAAI 2023 Annual Meeting that found 98% of participants experienced added anxiety when traveling due to their food allergy, with a "lamentingly high number" of negative experiences.